Is brigatinib/brigatinib a domestic drug or an imported drug?

Brigatinib/Brigatinib (Brigatinib), trade nameAlunbrig, is a drug produced by the biopharmaceutical companyAriad Oral targeted drugs developed by Pharmaceuticals (now a subsidiary of Takeda Pharmaceuticals) are mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). This drug is a second-generation ALK tyrosine kinase inhibitor (TKI) and is used as a progressive treatment regimen after overcoming resistance to first-generation ALK inhibitors (such as crizotinib). Brigatinib is a pure imported original drug, and its research, development and global marketing are led by international pharmaceutical giants.

At present, the drug has been approved in many countries and regions in the United States, Europe and Asia, and has been successfully introduced into the Chinese market, becoming an important treatment option for domesticALK-positive lung cancer patients. In 2022, brigatinib received marketing authorization in China and was quickly included in the national medical insurance drug catalog, greatly improving patient accessibility. However, although it has been launched in China, no domestic generic version of brigatinib has been officially approved for marketing in China. Some domestic pharmaceutical companies may be in the stage of generic drug research and development or clinical trials, but there is no official domestic version that has been successfully registered with the drug regulatory department and circulated in the market. This means that brigatinib that can be prescribed and purchased in Chinese hospitals and pharmacies is still an imported product.

For the majority of patients, although this status quo ensures the consistency of the quality and efficacy of the original drugs, it also faces certain pressure in terms of price. Therefore, many patients and doctors are also paying attention to whether domestic generic drugs will join the market in the future, which will hopefully provide patients with more cost-effective treatment options and help promote the popularization and long-term sustainability of ALK-positive lung cancer treatment.

Reference materials:https://www.alunbrig.com/